Latest revenue
$173.9M
as of 2026-03-31
Latest net income
$7.3M
as of 2026-03-31
Net margin
4.2%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $2.38B
- Enterprise value
- $2.38B
- P/E (trailing)
- 12.5×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $156.00
- 52-wk low
- $60.10
- Beta
- —
- Shares out
- 34.6M
5-year trend
What this company does
Item 1. Business. Overview We are a medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. We developed the OCS to replace a decades-old standard of care that we believe is significantly limiting access to life-saving transplant therapy for hundreds of thousands of patients worldwide. Our innovative OCS technology replicates many aspects of the organ’s natural living and functioning environment outside of the human body. As such, the OCS represents a paradigm shift that transforms organ preservation for transplantation from a static state to a dynamic environment that enables new capabilities, including organ…
AI summary unavailable — showing raw filing excerpt
Generated from TMDX's filing dated 2026-02-24
Key risks
Item 1A. Risk Factors. An investment in our common stock involves risks. The following risks and all of the other information contained in this Annual Report on Form 10-K should be considered carefully before investing in our common stock. The risks described below are those that we believe are the material risks that we face. If any of the following risks actually occurs, our business, prospects, operating results and financial condition could suffer materially, the trading price of our common stock could decline and investors could lose all or part of their investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not…
AI summary unavailable — showing raw filing excerpt
Generated from TMDX's filing dated 2026-02-24
Profitability
Gross margin
59.9%
0.9%Operating margin
17.9%
111.2%Net margin
31.4%
291.3%Return on equity
83.2%
222.0%Return on assets
17.8%
303.8%Leverage
Debt / equity
3.67×
24.4%Long-term debt / equity
0.22×
49.9%Debt / assets
78.6%
5.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $173.9M | +21.2% | $7.3M | -71.5% | 4.2% |
Q4 2025 2025-12-31 | $160.8M | +32.2% | $105.4M | +1436.9% | 65.6% |
Q3 2025 2025-09-30 | $143.8M | +32.2% | $24.3M | +476.8% | 16.9% |
Q2 2025 2025-06-30 | $157.4M | +37.7% | $34.9M | +186.3% | 22.2% |
Q1 2025 2025-03-31 | $143.5M | +48.2% | $25.7M | +110.6% | 17.9% |
Q4 2024 2024-12-31 | $121.6M | — | $6.9M | — | 5.6% |
Q3 2024 2024-09-30 | $108.8M | +63.7% | $4.2M | +116.6% | 3.9% |
Q2 2024 2024-06-30 | $114.3M | +117.9% | $12.2M | +1318.2% | 10.7% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Electromedical & Electrotherapeutic Apparatus · SIC 3845
Your notes
Keep private notes on TMDX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$3.0M
Insider selling
$5.4M
Net activity
−$2.4M
Distinct insiders
7
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns TMDX
Institutional value
$1.85B
Total shares held
18.9M
Distinct holders
265
-157 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 5.3M | $526.2M | -101.9K (-1.9%) | Trimmed |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.9M | $190.8M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 1.5M | $146.9M | — | New |
| 4 | Invesco Ltd. | 1.0M | $103.2M | +353.4K (+51.6%) | Added |
| 5 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 939.5K | $93.4M | -57.4K (-5.8%) | Trimmed |
| 6 | UBS Group AG | 580.8K | $57.7M | -78.5K (-11.9%) | Trimmed |
| 7 | DIMENSIONAL FUND ADVISORS LP | 516.7K | $51.4M | +27.0K (+5.5%) | Added |
| 8 | Capital World Investors | 374.2K | $37.2M | +146.7K (+64.5%) | Added |
| 9 | CITIGROUP INC | 357.4K | $35.5M | +285.3K (+396.1%) | Added |
| 10 | WASATCH ADVISORS LP | 346.1K | $34.4M | +14.3K (+4.3%) | Added |
| 11 | EMERALD ADVISERS, LLC | 342.8K | $34.1M | -8.6K (-2.4%) | Trimmed |
| 12 | BAILLIE GIFFORD & CO | 305.2K | $30.3M | -11.3K (-3.6%) | Trimmed |
| 13 | JPMORGAN CHASE & CO | 308.3K | $29.1M | -66.9K (-17.8%) | Trimmed |
| 14 | WELLS FARGO & COMPANY/MN | 273.8K | $27.2M | +15.3K (+5.9%) | Added |
| 15 | ROYCE & ASSOCIATES LP | 244.4K | $24.3M | +1.2K (+0.5%) | Added |
| 16 | VANGUARD FIDUCIARY TRUST CO | 236.4K | $23.5M | — | New |
| 17 | PRINCIPAL FINANCIAL GROUP INC | 231.4K | $23.0M | +37.7K (+19.4%) | Added |
| 18 | EMERALD MUTUAL FUND ADVISERS TRUST | 229.3K | $22.8M | -575 (-0.3%) | Trimmed |
| 19 | Bank of New York Mellon Corp | 211.4K | $21.0M | -7.2K (-3.3%) | Trimmed |
| 20 | DEUTSCHE BANK AG\ | 195.4K | $19.4M | +30.9K (+18.8%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once TMDX's latest filing finishes processing.